Trust linked to Phillip Frost adds 20K Cocrystal (COCP) shares

Rhea-AI Filing Summary

Cocrystal Pharma director and 10% owner Phillip Frost, M.D., reported an indirect open-market purchase of 20,000 shares of Cocrystal Pharma common stock. The shares were bought on February 24, 2026 at a weighted average price of $0.9976 per share in trades ranging from $0.98 to $1.00.

The purchased shares are held by Frost Gamma Investments Trust, an entity associated with Dr. Frost, which now holds 1,908,551 shares indirectly. Dr. Frost also holds 27,100 shares directly, including shares issuable upon vesting of restricted stock units, and disclaims beneficial ownership of the trust’s holdings except for any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

4400 BISCAYNE BLVD

(Street)

MIAMI FL 33137-3227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		P		20,000	A	$0.9976(1)	1,908,551	I	By Frost Gamma Investments Trust(2)
Common Stock								27,100(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.98 to $1.00, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.

2. These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. Includes shares of common stock issuable upon vesting of restricted stock units.

Remarks:

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

	/s/ Phillip Frost, MD ET AL	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for Cocrystal Pharma (COCP)?

Cocrystal Pharma reported an insider transaction where an entity associated with director and 10% owner Phillip Frost bought 20,000 common shares. The purchase was made in the open market, indicating increased indirect ownership through Frost Gamma Investments Trust.

How many Cocrystal Pharma (COCP) shares did the Frost-related trust buy and at what price?

Frost Gamma Investments Trust purchased 20,000 Cocrystal Pharma common shares at a weighted average price of $0.9976. Individual trades occurred within a range of $0.98 to $1.00 per share on February 24, 2026, according to the Form 4 disclosure.

How many Cocrystal Pharma (COCP) shares does the Frost-related trust hold after this transaction?

After the reported purchase, Frost Gamma Investments Trust holds 1,908,551 Cocrystal Pharma common shares indirectly. This figure reflects the updated position following the 20,000-share open-market acquisition disclosed in the Form 4 filing associated with Phillip Frost, M.D.

What is Phillip Frost’s direct ownership in Cocrystal Pharma (COCP) after the Form 4?

Phillip Frost directly owns 27,100 Cocrystal Pharma common shares after the reported transactions. This direct amount includes shares that may be issued upon vesting of restricted stock units, separate from the larger indirect holdings of Frost Gamma Investments Trust.

Does Phillip Frost claim full beneficial ownership of the trust’s Cocrystal Pharma (COCP) shares?

Phillip Frost disclaims full beneficial ownership of shares held by Frost Gamma Investments Trust, except for any pecuniary interest. The Form 4 explains the multi-entity structure and clarifies that the report should not be deemed an admission of beneficial ownership for Section 16 purposes.